Bluebird bio went from a high-flying $10 billion company in 2018 during the heyday of gene therapy to being sold for a measly $29 million upfront in a fire sale last month. But it almost wasn’t that dismal of an ending, especially for a biotech that achieved the rare feat of securing three FDA approvals for gene therapies, according to Friday morning regulatory filings that detail the deal process.
Read the full article: How bluebird’s Buyout Offer Went from $100M Upfront to $29M //
Source: https://endpts.com/how-bluebirds-buyout-offer-went-from-100m-upfront-to-29m